In light of the FLAURA2 data, which patients would you recommend upfront treatment with chemotherapy + osimertinib rather than osimertinib monotherapy?

The management of patients with advanced, classical (i.e., exon 19 deletion/L858R) EGFR mutation-positive NSCLC has been fairly straightforward since the approval of osimertinib for frontline management based on the outstanding results of the FLAURA study demonstrating significantly improved PFS and...